<DOC>
	<DOCNO>NCT00398008</DOCNO>
	<brief_summary>A randomized , double blind clinical trial compare buprenorphine naltrexone maintenance treatment combine drug abuse HIV risk reduction counsel ( DC-HIV ) heroin opium addict Iran .</brief_summary>
	<brief_title>HIV Risk Reduction Drug Abuse Treatment Iran</brief_title>
	<detailed_description>This randomize double blind clinical trial compare efficacy buprenorphine maintenance treatment ( BMT ) naltrexone maintenance treatment ( NMT ) recently detoxify opioid dependent patient ( N=130 ; 65 heroin dependent , 65 opium dependent—Specific Aim 1 ) . Manual-guided , HIV risk reduction drug counseling ( DC-HIV ) provide patient platform psychotherapy . Maintenance treatment provide 12 week patient ; patient may also continue receive maintenance treatment additional 12 week follow initial treatment period . Primary outcome measure , assess twice weekly urine toxicology test self-report first 12 week monthly 12-week extension , include resumption heroin use , 1 3 week continuous relapse reduction HIV risk behavior . The project also evaluate characteristic treatment-seeking opioid addict Iran ( include specific risk behavior pattern HIV risk behavior ; prevalence psychiatric medical comorbidity ; pattern social , family , vocational , criminal activity service needs—Specific Aim 2 ) . This data use revise DC-HIV manual address specific circumstance risk behavior opioid addict Iran provide data regard differential response opium compare heroin addict BMT NMT . Finally , project also provide clinical training health professional train mentor drug abuse treatment HIV prevention research clinical researcher continue development , implementation , evaluation dissemination HIV prevention drug abuse treatment approach Iran project end ( Specific Aim 3 ) . The Institute Cognitive Science Studies collaboratively fund project lead subsequent dissemination drug abuse HIV risk reduction effort Iran .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Opioid Dependence Dependence alcohol , benzodiazepines sedative Suicide homicide risk Psychotic disorder major depression Inability read understand protocol assessment question Lifethreatening unstable medical problem Greater 3 time normal liver enzyme ( AST , GGT )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>HIV risk reduction behavior</keyword>
	<keyword>Counseling</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>